Rybelsus vs Wegovy: approved uses, pill and pen, doses and cost
The short answer
Rybelsus vs Wegovy compares two semaglutide brands with separate labels. Rybelsus is a daily tablet approved for type 2 diabetes. Wegovy, a weekly pen or daily tablet, is approved for weight reduction and cardiovascular risk reduction. Wegovy tablets cost $149 to $299 a month self-pay through NovoCare Pharmacy.
Key takeaways
- Both are Novo Nordisk semaglutide, but each has its own label, strengths and approved uses.
- Rybelsus is approved for adults with type 2 diabetes. It has no weight-loss use.
- Wegovy is the semaglutide brand approved for long-term weight reduction, as a weekly pen or a daily tablet.
- Both tablets need the same morning routine: empty stomach, up to 4 ounces of water, then a 30-minute wait.
- The Wegovy label says use with other semaglutide products isn't recommended, so the two aren't taken together.
Rybelsus vs Wegovy, side by side
| Rybelsus | Wegovy | |
|---|---|---|
| Active ingredient | semaglutide | semaglutide |
| Maker | Novo Nordisk | Novo Nordisk |
| FDA-approved uses |
|
|
| How it is taken | daily (tablet) | weekly (single-dose pen); daily (tablet) |
| Strengths | 3 to 14 mg | 0.25 to 25 mg |
| Label starting dose |
|
|
| Cheapest verified self-pay | No self-pay price listed | $299 per fill at 25 mg |
| With covering commercial insurance | $25 with the manufacturer card | $25 with the manufacturer card |
| Medicare GLP-1 Bridge | No | Yes: Single-dose pen (7.2 mg pen is branded WEGOVY HD); Tablet (once daily) |
| Label | Revised: 1/2026 (DailyMed version 14) | Revised: 6/2026 (DailyMed version 19) |
| Reaction | Semaglutide tablets 14 mg | Placebo |
|---|---|---|
| Nausea | 20% | 6% |
| Abdominal Pain | 11% | 4% |
| Diarrhea | 10% | 4% |
| Decreased appetite | 9% | 1% |
| Vomiting | 8% | 3% |
| Constipation | 5% | 2% |
| Reaction | Wegovy injection 2.4 mg once weekly | Placebo |
|---|---|---|
| Nausea | 44% | 16% |
| Diarrhea | 30% | 16% |
| Vomiting | 24% | 6% |
| Constipation | 24% | 11% |
| Abdominal Pain | 20% | 10% |
| Headache | 14% | 10% |
Each table comes from that medicine's own trials. The trials differ in who was studied and for how long, so the percentages are not a head-to-head comparison.
Rybelsus and Wegovy are easy to confuse. Both are semaglutide, both are made by Novo Nordisk, and since Wegovy gained a tablet form, both can be a pill you take each morning. What keeps them apart is the label. Rybelsus is a type 2 diabetes medicine. Wegovy is a weight and cardiovascular-risk medicine. Each has its own strengths, schedule and coverage rules, and the Wegovy label says it shouldn’t be used with other semaglutide products. This page compares them using the FDA labels (Revised: 1/2026 (DailyMed version 14) for Rybelsus, Revised: 6/2026 (DailyMed version 19) for Wegovy) and our price records.
Rybelsus or Wegovy: which suits whom?
- You’re an adult with type 2 diabetes who wants semaglutide for blood sugar control without an injection. That’s Rybelsus.
- You’re being treated for obesity or overweight, or you’re an adult with established cardiovascular disease and excess weight. That’s Wegovy, the semaglutide brand with a weight-reduction use.
- You want a choice of form. Wegovy offers a weekly pen and a daily tablet. Rybelsus is a tablet only.
- You’re paying cash. Wegovy has published self-pay prices from $149 a month.
- You’re on Medicare. Rybelsus runs through Part D as a diabetes medicine. Wegovy for weight management runs through the Medicare GLP-1 Bridge, which people with type 2 diabetes can’t use.
- You’re looking ahead. Novo Nordisk states that Rybelsus is being replaced by the Ozempic pill.
Both brands contain semaglutide, but each has its own label and approved uses. If you take Rybelsus and want to talk about weight, ask your prescriber which label applies to you. Don’t try to work it out from the milligrams on the bottle.
What is each approved for?
Rybelsus has two uses, both in adults with type 2 diabetes: improving blood sugar control alongside diet and exercise, and reducing the risk of major adverse cardiovascular events (serious heart and blood vessel events) in those at high risk for them.
Wegovy has three kinds of use, and they depend on the form:
- Weight reduction. Injection: adults and children aged 12 and older with obesity, and adults with overweight and a weight-related condition. Tablets: adults with obesity, or with overweight and a weight-related condition.
- Cardiovascular risk. Injection and tablets: adults with established cardiovascular disease and either obesity or overweight.
- MASH (a liver condition). Injection only, under accelerated approval.
Both labels have a cardiovascular use, for different people. Rybelsus’s is tied to type 2 diabetes. Wegovy’s is tied to established cardiovascular disease with obesity or overweight.
The two pills: how alike are they?
This is the heart of the confusion, so it’s worth being exact.
What the two tablets share. Both are taken once daily, in the morning, on an empty stomach, with up to 4 ounces of water and no other liquid, followed by at least 30 minutes before food, other drinks or other oral medicines. Both labels say no more than one tablet a day. Both note a drug interaction study in which levothyroxine (a thyroid medicine) exposure rose 33% with the semaglutide tablet. Both are stored in the original bottle.
What they don’t share.
- Strengths: Rybelsus is 3 mg, 7 mg, 14 mg. Wegovy tablets are 1.5 mg, 4 mg, 9 mg, 25 mg.
- Schedule: Rybelsus runs 30 days at 3 mg, 30 days at 7 mg, then 14 mg if more blood sugar control is needed. Wegovy tablets run 30 days each at 1.5 mg, 4 mg and 9 mg, then the 25 mg maintenance dosage (the dose you stay on) from day 91.
Even within the diabetes label, Rybelsus and Ozempic tablets aren’t substitutable milligram for milligram.
The Wegovy label also has a note for readers with type 2 diabetes. It says some patients with type 2 diabetes taking Wegovy tablets may have subtherapeutic semaglutide blood concentrations (levels too low to work as intended). If response to the tablets is inadequate, it says alternatives should be considered, including Wegovy injection.
And the Wegovy pen?
Rybelsus has no injectable form. Wegovy does: a single-dose pen in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg, 7.2 mg, injected once a week on the same day, with or without meals. It starts at 0.25 mg and steps up every 4 weeks to the usual maintenance dosage of 2.4 mg from week 17. For adults taking it for weight reduction, 7.2 mg is an optional further step.
The pen vs vial vs pill comparer sets the per-fill costs of the forms side by side, and the titration schedule tool dates each step.
What does each cost?
Rybelsus. One price: with commercial insurance that covers Rybelsus, the savings offer lowers the cost to as little as $25.
Wegovy:
- Tablets, self-pay through NovoCare Pharmacy: $149 a month for 1.5 mg, $199 for 4 mg, and $299 for 9 mg and 25 mg.
- Pen, self-pay: $349 a month for 1 mg, 1.7 mg and 2.4 mg, and $399 for 7.2 mg.
- Savings offer with commercial insurance that covers Wegovy: as little as $25 a month.
- List price (the full price before any discount): $1,349.02 per package.
If you have no coverage, ask your pharmacy for a Rybelsus cash price. The Rybelsus cost page, the Wegovy cost page and the cost calculator have more.
Does insurance or Medicare cover them?
The label decides the coverage rules, even though the molecule is shared.
Commercial insurance. Rybelsus for type 2 diabetes is commonly covered, often with prior authorization (the plan’s approval before it pays) or a step requirement (trying another medicine first). Wegovy depends on whether your plan covers weight-management medicines, and some plans exclude them entirely. Call the number on your insurance card and ask about each brand for your diagnosis.
Medicare.
- Rybelsus: CMS lists type 2 diabetes as an indication eligible for Part D coverage, so it goes through your Part D plan.
- Wegovy: CMS says Medicare and Medicaid generally do not cover GLP-1 drugs for the weight loss indication. Part D can cover Wegovy when it’s prescribed to reduce cardiovascular risk in adults with established cardiovascular disease and obesity or overweight. For weight management, the Medicare GLP-1 Bridge covers the Wegovy pen and tablets at a $50 copay per one-month supply through December 31, 2027. People with type 2 diabetes aren’t eligible for the Bridge.
Both brands fall under one scheduled change: the negotiated Medicare price for a 30-day supply of semaglutide (Ozempic, Rybelsus, Wegovy) is $274 from January 1, 2027. That’s a Part D price, and it doesn’t by itself make Wegovy covered for weight loss. See does Medicare cover Wegovy and the Medicare guide.
How do the side effects compare?
Gastrointestinal (stomach and bowel) reactions are the most common on both labels. The trials differed in patients, doses and purpose, so each set of figures stands alone.
Rybelsus. In its placebo-controlled trials in adults with type 2 diabetes, nausea was reported by 11 percent of patients on 7 mg and 20 percent on 14 mg, versus 6 percent on placebo.
Wegovy injection. In the adult weight-reduction trials of 2.4 mg, nausea was reported by 44 percent of patients, versus 16 percent on placebo, and vomiting by 24 percent, versus 6 percent. Overall, 73% of patients on Wegovy injection and 47% on placebo reported a gastrointestinal reaction.
Wegovy tablets. The label gives no separate table. It says the types and frequency of common reactions in the 25 mg tablet trial were similar to those of the injection. In that trial, 6.9% of patients on the tablets and 5.9% on placebo permanently stopped treatment because of adverse reactions.
Both labels carry the boxed warning about thyroid C-cell tumors, with the same rule against use by people with a personal or family history of medullary thyroid carcinoma (a type of thyroid cancer) or MEN 2 (an inherited condition linked to it). Both say to stop the medicine at least 2 months before a planned pregnancy. Both warn about low blood sugar with insulin or a sulfonylurea (a type of diabetes medicine) and about diabetic retinopathy complications (eye problems from diabetes) in people with type 2 diabetes.
Can you switch between Rybelsus and Wegovy?
Not by matching tablets. The labels cover other moves and leave this one out:
- The Rybelsus label describes switching with Ozempic tablets, and from the Ozempic 0.5 mg injection.
- The Wegovy label describes switching between its own 2.4 mg injection and 25 mg tablets.
- The Wegovy label says using Wegovy with other semaglutide-containing products isn’t recommended.
So a change from Rybelsus to Wegovy, or back, is a new prescription for a different product. Your prescriber decides the starting dose and the timing, and we don’t convert doses.
Our switching guides and the switching planner show the label text for each product. For neighboring comparisons, see Rybelsus vs Ozempic, Mounjaro vs Wegovy or the full comparison hub.
Frequently asked questions
Are Rybelsus and Wegovy the same drug?
Both contain semaglutide and both are made by Novo Nordisk, but they're separate products with their own labels, strengths and approved uses. Rybelsus tablets (3 mg, 7 mg, 14 mg) are approved for adults with type 2 diabetes. Wegovy, as a pen or as tablets (1.5 mg, 4 mg, 9 mg, 25 mg), is approved for weight reduction and cardiovascular risk reduction.
Is the Wegovy pill just a higher dose of Rybelsus?
The labels don't describe it that way, and you shouldn't think of it that way either. Wegovy tablets and Rybelsus have different strengths, different dose schedules and different approved uses. The Wegovy label says using Wegovy with other semaglutide products isn't recommended.
Can I take Rybelsus for weight loss?
Rybelsus has no weight-loss use. Its label lists blood sugar control and cardiovascular risk reduction in adults with type 2 diabetes. The semaglutide brand approved for long-term weight reduction is Wegovy. Which one a prescriber writes depends on your diagnosis, and insurers cover the two under different rules.
Which costs more, Rybelsus or Wegovy?
Wegovy has self-pay prices: $149 to $299 a month for tablets and $349 for the 1 mg to 2.4 mg pens. With commercial coverage, each brand's savings offer lowers the cost to as little as $25.
Can I switch from Rybelsus to Wegovy?
Only with a new prescription from your prescriber, who decides the starting dose. The Wegovy label gives starting dosages (0.25 mg weekly for the pen, 1.5 mg daily for the tablets) and switching instructions only between Wegovy's own forms. It also says Wegovy shouldn't be taken with other semaglutide-containing products, so the two aren't overlapped.
Sources (31)
- 1.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 2.1
“Take one RYBELSUS or OZEMPIC tablet orally once daily on an empty stomach in the morning with water (up to 4 ounces of water). Do not take RYBELSUS or OZEMPIC tablets with other liquids besides water”
- 2.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 2.1
“After taking RYBELSUS or OZEMPIC tablets, wait at least 30 minutes before eating food, drinking beverages or taking other oral medications”
- 3.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 2.1
“Do not take more than one tablet per day.”
- 4.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 2.2
“Starting Dosage (Initiation Phase) (Days 1 to 30): The recommended starting dosage is 3 mg orally once daily (this dosage is not effective for glycemic control).”
- 5.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 2.1
“RYBELSUS and OZEMPIC tablets are not substitutable on a mg-to-mg basis.”
- 6.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 16
“Store RYBELSUS and OZEMPIC tablets at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Store and dispense in the original bottle.”
- 7.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 7.2
“Levothyroxine exposure was increased 33% (90% CI: 1.25 to 1.42) when administered with semaglutide tablets in a drug interaction study”
- 8.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 8.3
“Discontinue RYBELSUS or OZEMPIC tablets in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide”
- 9.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 4
“A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)”
- 10.FDA label (DailyMed): Wegovy prescribing information, section 2.1
“Take one WEGOVY tablet orally once daily on an empty stomach in the morning with water (up to 4 ounces). Do not take WEGOVY tablets with other liquids besides water”
- 11.FDA label (DailyMed): Wegovy prescribing information, section 2.1
“After taking a WEGOVY tablet, wait at least 30 minutes before eating food, drinking beverages or taking other oral medications”
- 12.FDA label (DailyMed): Wegovy prescribing information, section 2.1
“Do not take more than one tablet per day.”
- 13.FDA label (DailyMed): Wegovy prescribing information, section 16
“Store WEGOVY tablet in the original bottle until use to protect tablets from moisture. Store WEGOVY tablets in a dry place away from moisture.”
- 14.FDA label (DailyMed): Wegovy prescribing information, section 2.1
“Administer WEGOVY injection once weekly, on the same day each week, at any time of day, with or without meals.”
- 15.FDA label (DailyMed): Wegovy prescribing information, section 7.2
“In a drug interaction study with the semaglutide tablet, levothyroxine exposure was increased 33% (90% CI: 1.25-1.42). Monitor the effects of oral medications concomitantly administered with WEGOVY.”
- 16.FDA label (DailyMed): Wegovy prescribing information, section 1
“Concomitant use of WEGOVY (semaglutide) tablets or WEGOVY (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.”
- 17.FDA label (DailyMed): Wegovy prescribing information, section 2.5
“One week after discontinuing WEGOVY 2.4 mg injection, initiate 25 mg of WEGOVY tablets orally once daily.”
- 18.FDA label (DailyMed): Wegovy prescribing information, section 2.5
“The day after discontinuing WEGOVY tablets 25 mg once daily, initiate WEGOVY 2.4 mg subcutaneous injection once weekly.”
- 19.FDA label (DailyMed): Wegovy prescribing information, section 8.3
“Because of the potential for fetal harm, discontinue WEGOVY in patients at least 2 months before they plan to become pregnant to account for the long half-life of semaglutide”
- 20.FDA label (DailyMed): Wegovy prescribing information, section 4
“a personal or family history of MTC or in patients with MEN 2”
- 21.CMS: Information for Part D Plans
“Type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis) indications are eligible for Part D coverage. [...] If a Medicare Part D beneficiary has a prescription for a GLP-1 drug for an indication covered under Medicare Part D, they should continue to obtain their GLP-1 through their Part D plan.”
- 22.CMS: BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model
“GLP-1 drugs for weight loss, along with lifestyle interventions, can help people improve their overall health, but GLP-1s are expensive and currently Medicare and Medicaid generally do not cover these drugs for the weight loss indication.”
- 23.CMS: Information for Part D Plans
“Beneficiaries who are prescribed an eligible GLP-1 drug for a use that is coverable under the basic Medicare Part D benefit, regardless of whether the eligible GLP-1 drug is on the Part D plan’s formulary (e.g., Zepbound® for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity; Wegovy® to reduce the risk of major adverse cardiovascular (CV) events in adults with established CV disease and either obesity or overweight) would not qualify for coverage of that eligible GLP-1 drug under the Medicare GLP-1 Bridge. Part D plan sponsors must continue to follow their existing formulary exception processes for these requests.”
- 24.CMS: Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027
“Below is the list of negotiated prices, which the statute refers to as maximum fair prices (MFPs), for the 15 selected drugs covered under Medicare Part D that will go into effect beginning January 1, 2027, based on negotiations and agreements reached between CMS and participating drug companies. [table] Drug Name: Ozempic; Rybelsus; Wegovy. Participating Drug Company: Novo Nordisk Inc. Agreed to Negotiated Price for 30-day Supply for CY 2027: $274. List Price for 30-day Supply, CY 2024: $959. Discount of Negotiated Price from 2024 List Price: 71%.”
- 25.CMS: Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027
“For example, for the selected drug with the highest total gross covered prescription drug costs under Part D in 2024, Ozempic; Rybelsus; Wegovy, the MFP applied across three commonly used dosage forms and strengths will be: [table] NDC-11: 00169-4524-14. Description of package: 2.4mg/0.75mL Pen, 4 Pens (Wegovy). MFP per package: $385.63.”
- 26.
- 27.
- 28.
- 29.
- 30.
- 31.
Related pages
- Rybelsus (semaglutide tablets): uses, doses, cost and how to take it
- What is Wegovy? Uses, doses, pill and pen, and cost
- Rybelsus vs Ozempic: tablet or pen, doses, cost and switching
- Foundayo vs Rybelsus: uses, how to take them, doses and cost
- Cost calculator
- Saxenda vs Wegovy: daily or weekly, approved uses, cost and coverage
